Identifying and assessing the extent suspected skin cancer defined as Basal Cell Carcinoma, Lentigo Maligna or Melanoma in Situ in patients scheduled to have a surgical excision. Cancer
Conditions
Interventions
Participants scheduled to have a surgical excision will undergo the study procedures on the day of their operation, prior to the surgical procedure.
Firstly, participants will have their area of inte
once to acquire images of a control area similar to the area of interest, but clinically free from obvious pathology
and lastly they will undergo a scan of the area of interest (suspected skin cancer). A good quality scan will be needed from each area, and may need repeating if the signal acquisition is inadequate.
Sponsors
University Hospitals Coventry and Warwickshire NHS Trust
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. NHS patients attending University Hospitals Coventry and Warwickshire 2. Area of interest accessible for THz scan 3. Aged 18 years and over 4. Suspected skin cancer defined as: 4.1. lesions clinically suspicious for Basal Cell Carcinoma (BCC) 4.2. biopsy proven BBC 4.3. biopsy proven Lentigo Maligna (LM) 4.4. Melanoma in Situ (MiS) 5. Capacity to give informed consent
Exclusion criteria
Exclusion criteria: 1. Confirmed biopsy proven other skin cancer at the same area of interest 2. Absence of suspected or confirmed skin cancer as described in the inclusion criteria 3. Unable to consent to the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Measured at baseline using the screening/recruitment log which clinical research staff will manage, collated safety monitoring reports (AEs/SAEs) and study database output: 1.Number of patients screened, eligible, recruited and withdrawn 2.Patient willingness to participate in the trial 3.Participant tolerance of the device 4.Number of participants with complete datasets | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Terahertz scan data and the formal reported histological analysis as part of the standard skin cancer management pathway 2. Histology results collected post-surgery | — |
Countries
England, United Kingdom
Contacts
Public ContactCristiana Huhulea
Outcome results
None listed